Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 10Terminated 4Unknown 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 11Neoplasm Metastasis 7Neoplasms 5Carcinoma, Renal Cell 3Tuberous Sclerosis 2Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Neuroendocrine Tumors 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Neuroendocrine 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Renal Cell Cancer Metastatic 1Relapsed Pediatric Solid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Metatropic dwarfism 1Melanoma 1Lymphoma 1Liver Neoplasms 1Liver Failure 1Liver Diseases 1Liver Cirrhosis 1Leukemia, Myelomonocytic, Acute 1

Interventions

Docetaxel 21Radiosurgery 19Radiotherapy 17Androgen Antagonists 14Leuprolide 11Goserelin 11bicalutamide 9enzalutamide 8Surveys and Questionnaires 8Prednisone 8Brachytherapy 8Blood Specimen Collection 8Abiraterone Acetate 8acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 7Radiotherapy, Intensity-Modulated 7Multiparametric Magnetic Resonance Imaging 7Gonadotropin-Releasing Hormone 7Triptorelin Pamoate 6pembrolizumab 4cabazitaxel 4abiraterone 4Standard of Care 4Positron Emission Tomography Computed Tomography 4Metformin 4Heavy Ion Radiotherapy 4Exercise 4Estramustine 4luprolide acetate gel depot 3darolutamide 3Watchful Waiting 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Prostatic Neoplasms × Everolimus × Clear all
NCT03580239 2018-07-09

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Tianjin Medical University Second Hospital

Phase 3 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT00657982 2009-01-21

Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer

Sheba Medical Center

Phase 2 Unknown
15 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡